Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 52.82 Billion KRW | 11.39% |
| 2022 | 47.42 Billion KRW | 2.1% |
| 2021 | 46.44 Billion KRW | 18.13% |
| 2020 | 39.31 Billion KRW | -18.62% |
| 2019 | 48.3 Billion KRW | 78.78% |
| 2018 | 27.02 Billion KRW | 23.69% |
| 2017 | 21.84 Billion KRW | 14.66% |
| 2016 | 19.05 Billion KRW | 102.33% |
| 2015 | 9.41 Billion KRW | 104.41% |
| 2014 | 4.6 Billion KRW | 57.19% |
| 2013 | 2.93 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 13.41 Billion KRW | 8.69% |
| 2024 Q1 | 12.34 Billion KRW | -22.86% |
| 2023 FY | 52.82 Billion KRW | 11.39% |
| 2023 Q3 | 12.05 Billion KRW | -2.38% |
| 2023 Q1 | 12.42 Billion KRW | -10.37% |
| 2023 Q4 | 16 Billion KRW | 32.81% |
| 2023 Q2 | 12.34 Billion KRW | -0.65% |
| 2022 Q4 | 13.86 Billion KRW | 19.08% |
| 2022 FY | 47.42 Billion KRW | 2.1% |
| 2022 Q3 | 11.64 Billion KRW | 8.68% |
| 2022 Q2 | 10.71 Billion KRW | -4.41% |
| 2022 Q1 | 11.2 Billion KRW | -19.1% |
| 2021 FY | 46.44 Billion KRW | 18.13% |
| 2021 Q4 | 13.85 Billion KRW | 28.05% |
| 2021 Q2 | 11.13 Billion KRW | 4.76% |
| 2021 Q1 | 10.63 Billion KRW | 1806.58% |
| 2021 Q3 | 10.81 Billion KRW | -2.9% |
| 2020 FY | 39.31 Billion KRW | -18.62% |
| 2020 Q1 | 21.69 Billion KRW | 118.87% |
| 2020 Q2 | 20.06 Billion KRW | -7.53% |
| 2020 Q3 | 448.87 Million KRW | -97.76% |
| 2020 Q4 | 557.76 Million KRW | 24.26% |
| 2019 Q3 | 22.23 Billion KRW | -44.1% |
| 2019 Q1 | 23.75 Billion KRW | 14.18% |
| 2019 FY | 48.3 Billion KRW | 78.78% |
| 2019 Q4 | 9.91 Billion KRW | -55.4% |
| 2019 Q2 | 39.76 Billion KRW | 67.43% |
| 2018 Q2 | 16.8 Billion KRW | 166.09% |
| 2018 FY | 27.02 Billion KRW | 23.69% |
| 2018 Q4 | 20.8 Billion KRW | 177.18% |
| 2018 Q3 | 7.5 Billion KRW | -55.35% |
| 2018 Q1 | 6.31 Billion KRW | -47.65% |
| 2017 FY | 21.84 Billion KRW | 14.66% |
| 2017 Q1 | 6.35 Billion KRW | 19.28% |
| 2017 Q2 | 5.23 Billion KRW | -17.74% |
| 2017 Q3 | 4.96 Billion KRW | -5.01% |
| 2017 Q4 | 12.06 Billion KRW | 142.78% |
| 2016 FY | 19.05 Billion KRW | 102.33% |
| 2016 Q4 | 5.33 Billion KRW | 6.3% |
| 2016 Q3 | 5.01 Billion KRW | 10.86% |
| 2016 Q2 | 4.52 Billion KRW | -15.03% |
| 2016 Q1 | 5.32 Billion KRW | 36.11% |
| 2015 Q3 | 1.8 Billion KRW | 22.33% |
| 2015 Q2 | 1.47 Billion KRW | 39.59% |
| 2015 Q1 | 1.05 Billion KRW | -23.41% |
| 2015 FY | 9.41 Billion KRW | 104.41% |
| 2015 Q4 | 3.91 Billion KRW | 116.32% |
| 2014 Q2 | 1.49 Billion KRW | 61.61% |
| 2014 Q1 | 926.62 Million KRW | -2.85% |
| 2014 Q3 | 799.9 Million KRW | -46.58% |
| 2014 Q4 | 1.38 Billion KRW | 72.87% |
| 2014 FY | 4.6 Billion KRW | 57.19% |
| 2013 Q4 | 953.77 Million KRW | -22.24% |
| 2013 FY | 2.93 Billion KRW | 0.0% |
| 2013 Q2 | 470.38 Million KRW | 23.33% |
| 2013 Q3 | 1.22 Billion KRW | 160.76% |
| 2013 Q1 | 381.38 Million KRW | 0.0% |
| 2012 Q3 | 548.86 Million KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 51.973% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -573.267% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 5.123% |
| Bioneer Corporation | 204.55 Billion KRW | 74.177% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -582.456% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 19.125% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -63.186% |
| Helixmith Co., Ltd | 37.36 Billion KRW | -41.363% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 81.526% |
| Medy-Tox Inc. | 110.88 Billion KRW | 52.362% |
| Peptron, Inc. | 16.65 Billion KRW | -217.132% |
| Genexine, Inc. | 41.62 Billion KRW | -26.893% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -226.746% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 46.437% |
| ALTEOGEN Inc. | 40.93 Billion KRW | -29.041% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 40.941% |
| SillaJen, Inc. | 5.11 Billion KRW | -933.271% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -105.824% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -49.855% |
| Genomictree Inc. | 16.26 Billion KRW | -224.77% |
| MedPacto, Inc. | 26.91 Billion KRW | -96.228% |
| D&D Pharmatech | 32.16 Billion KRW | -64.235% |
| EASY BIO,Inc. | 29.67 Billion KRW | -78.025% |
| GI Innovation, Inc. | 57.59 Billion KRW | 8.282% |